Aerie Pharma 
Welcome,         Profile    Billing    Logout  
 5 Products   2 Diseases  5 Products   8 Trials   465 News 
22 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rhopressa (netarsudil) / Alcon
NTG, NCT04981886: Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Not yet recruiting
4
115
US
Netarsudil Ophthalmic, Rhopressa, Bimatoprost Ophthalmic, Lumigan
Salus University
Normal Tension Glaucoma
07/22
08/22
NCT06449352: Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Recruiting
4
100
US
Netarsudil, Brimonidine
Westlake Eye Specialists, Sengi
Normal Tension Glaucoma
06/25
06/25
NCT06865144: Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Recruiting
4
70
US
Netarsudil ophthalmic solution 0.02%, Rhopressa, Artificial tears
East Coast Institute for Research, Alcon, a Novartis Company, Florida Eye Specialists
Primary Open Angle Glaucoma or Ocular Hypertension
04/26
04/26
NCT07048886: Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Not yet recruiting
4
68
US
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Center for Sight Las Vegas
Primary Open Angle Glaucoma
12/26
12/26
NCT05660447: A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Active, not recruiting
2/3
80
US
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Rhopressa, Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud, Geri-Care Artificial Tears
Wills Eye
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
12/24
01/25
NCT06394973: Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Active, not recruiting
2
126
US
T4090 0.2%, T4090 0.3%, Rhopressa®
Laboratoires Thea
Glaucoma, Ocular Hypertension
05/25
05/25
NCT06033703: Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment

Not yet recruiting
1/2
48
NA
Netarsudil Ophthalmic, Rhopressa
Massachusetts Eye and Ear Infirmary
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
09/25
12/25
NCT01965197: Phase 1 Study of AR-13324 Ophthalmic Solution

Not yet recruiting
1
16
US
AR-13324 Ophthalmic Solution, 0.02%
Aerie Pharmaceuticals
Normal Volunteers
12/13
12/13
NCT04752020: Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Completed
1
25
US
Netarsudil Ophthalmic
Massachusetts Eye and Ear Infirmary
Fuchs' Endothelial Dystrophy
06/23
12/23
NCT06960629: The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

Enrolling by invitation
N/A
50
RoW
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo
University Hospital Dubrava
Pseudophakic Bullous Keratopathy, Glaucoma
04/26
10/26
NCT06969586: The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Enrolling by invitation
N/A
50
RoW
Netarsudil 0.02% Ophthalmic Solution, artificial tear substitute
University Hospital Dubrava
Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma
04/26
10/26
Rocklatan (latanoprost/netarsudil) / Alcon
NCT05283395: Rocklatan® Evaluation

Completed
4
136
US
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Rocklatan®
Aerie Pharmaceuticals
Glaucoma
03/23
03/23
NCT06883123: Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Recruiting
4
70
US
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Prairie Eye Center, Sengi
Open Angle Glaucoma
04/26
04/26
GLR305-E001, NCT06441643: Next Generation Rocklatan

Recruiting
2
450
US
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Latanoprost, Netarsudil 0.02% Ophthalmic Solution, Rhopressa®, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, Rocklatan®, AR-17043 Vehicle
Alcon Research
Open Angle Glaucoma, Ocular Hypertension
11/25
11/25
NCT06819046: Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

Recruiting
N/A
70
US
Rocklatan, Systane Ultra
Colorado Ophthalmology Associates PC, Sengi
Glaucoma
01/26
01/26
Tryptyr (acoltremon ophthalmic solution) / Alcon
COMET-2, NCT05285644: Study Evaluating the Safety and Efficacy of AR-15512

Completed
3
465
US
AR 15512 Ophthalmic Solution, Vehicle
Aerie Pharmaceuticals
Dry Eye Disease
07/23
07/23
COMET-3, NCT05360966: Study Evaluating the Safety and Efficacy of AR-15512

Completed
3
467
US
AR-15512 Ophthalmic Solution, Vehicle
Aerie Pharmaceuticals
Dry Eye Disease
10/23
10/23
COMET-4, NCT05493111: A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

Completed
3
275
US
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Aerie Pharmaceuticals
Dry Eye Disease
02/24
02/24
NCT06544694: A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

Completed
3
79
US
0.003% AR-15512, Artificial Tears, REFRESH® Classic
Alcon Research
Dry Eye Disease
03/25
03/25
NCT06544707: A Study Designed to Evaluate Tear Production

Completed
3
81
US
0.003% AR-15512
Alcon Research
Dry Eye Disease
01/25
01/25
NCT06660290: A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Completed
3
55
US
0.003% AR-15512 ophthalmic solution, REFRESH® Classic ophthalmic solution
Alcon Research
Dry Eye Disease
02/25
02/25
axitinib sustained release bioerodible implant (AR-14034 SR) / Alcon
NOVA-1, NCT05769153: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
1/2
140
US
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Alcon Research, Alcon Research
Neovascular Age-related Macular Degeneration (nAMD)
09/27
09/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rhopressa (netarsudil) / Alcon
NTG, NCT04981886: Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Not yet recruiting
4
115
US
Netarsudil Ophthalmic, Rhopressa, Bimatoprost Ophthalmic, Lumigan
Salus University
Normal Tension Glaucoma
07/22
08/22
NCT06449352: Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Recruiting
4
100
US
Netarsudil, Brimonidine
Westlake Eye Specialists, Sengi
Normal Tension Glaucoma
06/25
06/25
NCT06865144: Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Recruiting
4
70
US
Netarsudil ophthalmic solution 0.02%, Rhopressa, Artificial tears
East Coast Institute for Research, Alcon, a Novartis Company, Florida Eye Specialists
Primary Open Angle Glaucoma or Ocular Hypertension
04/26
04/26
NCT07048886: Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Not yet recruiting
4
68
US
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Center for Sight Las Vegas
Primary Open Angle Glaucoma
12/26
12/26
NCT05660447: A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Active, not recruiting
2/3
80
US
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Rhopressa, Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud, Geri-Care Artificial Tears
Wills Eye
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
12/24
01/25
NCT06394973: Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Active, not recruiting
2
126
US
T4090 0.2%, T4090 0.3%, Rhopressa®
Laboratoires Thea
Glaucoma, Ocular Hypertension
05/25
05/25
NCT06033703: Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment

Not yet recruiting
1/2
48
NA
Netarsudil Ophthalmic, Rhopressa
Massachusetts Eye and Ear Infirmary
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
09/25
12/25
NCT01965197: Phase 1 Study of AR-13324 Ophthalmic Solution

Not yet recruiting
1
16
US
AR-13324 Ophthalmic Solution, 0.02%
Aerie Pharmaceuticals
Normal Volunteers
12/13
12/13
NCT04752020: Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Completed
1
25
US
Netarsudil Ophthalmic
Massachusetts Eye and Ear Infirmary
Fuchs' Endothelial Dystrophy
06/23
12/23
NCT06960629: The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

Enrolling by invitation
N/A
50
RoW
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo
University Hospital Dubrava
Pseudophakic Bullous Keratopathy, Glaucoma
04/26
10/26
NCT06969586: The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Enrolling by invitation
N/A
50
RoW
Netarsudil 0.02% Ophthalmic Solution, artificial tear substitute
University Hospital Dubrava
Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma
04/26
10/26
Rocklatan (latanoprost/netarsudil) / Alcon
NCT05283395: Rocklatan® Evaluation

Completed
4
136
US
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Rocklatan®
Aerie Pharmaceuticals
Glaucoma
03/23
03/23
NCT06883123: Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Recruiting
4
70
US
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Prairie Eye Center, Sengi
Open Angle Glaucoma
04/26
04/26
GLR305-E001, NCT06441643: Next Generation Rocklatan

Recruiting
2
450
US
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Latanoprost, Netarsudil 0.02% Ophthalmic Solution, Rhopressa®, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, Rocklatan®, AR-17043 Vehicle
Alcon Research
Open Angle Glaucoma, Ocular Hypertension
11/25
11/25
NCT06819046: Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

Recruiting
N/A
70
US
Rocklatan, Systane Ultra
Colorado Ophthalmology Associates PC, Sengi
Glaucoma
01/26
01/26
Tryptyr (acoltremon ophthalmic solution) / Alcon
COMET-2, NCT05285644: Study Evaluating the Safety and Efficacy of AR-15512

Completed
3
465
US
AR 15512 Ophthalmic Solution, Vehicle
Aerie Pharmaceuticals
Dry Eye Disease
07/23
07/23
COMET-3, NCT05360966: Study Evaluating the Safety and Efficacy of AR-15512

Completed
3
467
US
AR-15512 Ophthalmic Solution, Vehicle
Aerie Pharmaceuticals
Dry Eye Disease
10/23
10/23
COMET-4, NCT05493111: A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

Completed
3
275
US
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Aerie Pharmaceuticals
Dry Eye Disease
02/24
02/24
NCT06544694: A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

Completed
3
79
US
0.003% AR-15512, Artificial Tears, REFRESH® Classic
Alcon Research
Dry Eye Disease
03/25
03/25
NCT06544707: A Study Designed to Evaluate Tear Production

Completed
3
81
US
0.003% AR-15512
Alcon Research
Dry Eye Disease
01/25
01/25
NCT06660290: A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Completed
3
55
US
0.003% AR-15512 ophthalmic solution, REFRESH® Classic ophthalmic solution
Alcon Research
Dry Eye Disease
02/25
02/25
axitinib sustained release bioerodible implant (AR-14034 SR) / Alcon
NOVA-1, NCT05769153: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
1/2
140
US
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Alcon Research, Alcon Research
Neovascular Age-related Macular Degeneration (nAMD)
09/27
09/27

Download Options